ZYBERNO
Stock Report
Updated Sep 1, 2026

DYADIC INTERNATIONAL, INC. (DYAI)

Healthcare • NASDAQ

$0.56

Professional Investment Analysis

ZYBERNO SCORE
Is it a great business? Is it getting better?
15.0/100
POOR BUSINESS
DYADIC INTERNATIONAL, INC. (DYAI) scores 15/100 — concerning metrics indicating significant structural or financial risks.
📊 How is the Zyberno Score calculated? +
VALUATION SIGNAL
N/A (Requires more data)
Requires fair value calculation and current price data
💰 How is Margin of Safety calculated? +
📈 How is Brina Gap calculated? +

Critical Financial Health Indicators

Return on Equity (Profitability):CRITICAL (-2,918.1%)
Debt-to-Equity (Solvency Risk):EXCELLENT (0.00x)
Operating Margin (Operational Efficiency):CRITICAL (-195.1%)
Return on Capital (Capital Efficiency):CRITICAL (-320.4%)
📊 Valuation Trilogy
Three interconnected metrics for complete valuation analysis
Click any metric for full methodology and detailed analysis
Zyberno's Verdict

DYADIC INTERNATIONAL, INC. (DYAI) stock report — Zyberno Score 15/100 (POOR BUSINESS). Full financial analysis on Zyberno.

DIVISION I: EXECUTIVE SUMMARY
A. Market Valuation

Market Price & Capitalization (2)

Current Price:0.56
Market Cap:$20.23M

Valuation Multiples (2)

P/S Ratio:5.32x
Peg Ratio:-999.00x

Enterprise Metrics (1)

Enterprise Value:$15.47M

Price Action & Momentum (3)

Momentum Percentile:29 / 100
% of 52-Week High:34.7%
B. Profitability Assessment

Return Metrics (5)

ROA:-84.8%
Reinvestment Rate:0.0%
Fundamental Growth Rate (g):0.0%

Margin Analysis (3)

Operating Margin Ttm:-195.1%
Net Margin Ttm:-200.5%
Ebitda Margin:-195.1%

TTM Performance (2)

Operating Margin Ttm:-195.1%
Net Margin Ttm:-200.5%

Yield Metrics (2)

Earnings Yield:-$29.67
Dividend Yield:0.0%
C. Log-Linear Regression Growth Trends

Earnings Surprise (SUE) (3)

EPS Surprise vs Expected:25.0%
Latest Earnings Filed:2026-08-12

Revenue Growth (Linear) (1)

Revenue Growth Rate (Linear):-0.5%
D. Financial Stability

Liquidity Ratios (3)

Current Ratio:1.65x
Quick Ratio:1.65x
Cash Ratio:1.24x

Leverage Analysis (1)

Debt To Ebitda:-999.00x

Coverage Ratios (1)

Times Interest Earned:-999.00

Capital Structure (4)

Working Capital:2,523,999.00
Cash And Cash Equivalents:4,800,000.00
Long Term Debt:$34.62K
Net Debt:-$4.76M
DIVISION II: FINANCIAL STATEMENTS ANALYSIS
A. Income Statement Analysis

Revenue Components (2)

Revenue TTM: $3.80M
Linear Growth: -50.0%
📊 Click to view full DYAI Revenue analysis & methodology →
Cost Of Revenue Ttm:$2.32M

Profitability Breakdown (2)

Gross profit TTM: $770.49K
Linear Growth: 2.2%
📊 Click to view full DYAI Gross Profit analysis & methodology →
-$7.42M

Bottom Line Performance (3)

-$7.62M
Income Before Tax:-$7.33M
Ebitda Ttm:-7,418,170.00

Operating Expenses (5)

Operating Expenses:11,220,407.00
R And D Expense:1,838,998.00
Sga Expense:6,173,961.00
Income Tax Expense:$31.32K
Interest Expense:0.00

Expense Ratios (3)

R And D To Revenue Percentage:191.3%
Sga To Revenue Percentage:642.4%
Ebitda Margin:-195.1%
B. Balance Sheet Analysis

Asset Composition (5)

Total Assets:$6.54M
Current Assets:$6.41M
Ppe Net:0.00
Goodwill:0.00
Intangible Assets:$0.00

Liability Structure (4)

Total Liabilities:8,923,775.00
Current Liabilities:3,882,765.00
Long Term Debt:$34.62K
Short Term Debt:$5.05K

Equity & Capital (3)

Equity:-$2.39M
Retained Earnings:-$97.53M
Common Stock:100,000,000.00

Working Capital Items (3)

Accounts Receivable:1,302,439.00
Inventory:0.00
Accounts Payable:816,059.00

Special Items (2)

Contract Liabilities:1,564,172.00
Stock Based Compensation:144,372.00
C. Cash Flow Analysis

Operating Activities (2)

-$5.72M$0.00

Investment Activities (1)

Investing Cash Flow:$1.27M

Financing Activities (3)

Financing Cash Flow:-$1.00
Dividends Paid Ttm:0.00
Stock Repurchase:0.00

Capital Transactions (3)

Common Stock Issuance:5,749,400.00
Long Term Debt Issuance:$0.00
Long Term Debt Repayments:$0.00
DIVISION III: OPERATIONAL METRICS
A. Per Share Analysis

Earnings Per Share (3)

EPS (Basic TTM):-0.21
-$0.23
Earnings Per Share Ttm:-$0.21

Revenue & Cash Per Share (2)

Sales Per Share Ttm:0.10
Operating Cash Flow Per Share:-$0.16

Book Value & Capital (2)

Book Value Per Share:-$0.07
Cash Per Share:0.13

Dividend Policy (1)

Dividend Payout Ratio:-999.00x
B. Operational Efficiency

Asset Utilization (2)

Asset Turnover Ttm:0.42x
Working Capital Turnover Ttm:1.51x

Receivables Management (2)

Receivables Turnover Ttm:2.92x
Days Sales Outstanding Ttm:125.03

Inventory Management (2)

Inventory Turnover Ttm:-999.00x
Days Inventory Outstanding Ttm:-999.00

Payables & Cash Cycle (2)

Days Payable Outstanding:128.40
Cash Conversion Cycle:-1,002.37
C. Quality & Risk Metrics

Financial Quality Scores (2)

Financial Strength Score:60.00
Quality Score:30.00

Market Metrics (2)

Beta:0.00x
Volatility Category:unknown
DIVISION IV: INVESTMENT ANALYSIS
A. Value Investment Framework

Damodaran Growth Analysis (2)

Reinvestment Rate:0.0%
Fundamental Growth Rate (g):0.0%
B. Log-Linear Regression Growth Analysis

Growth Rates (Log-Linear Regression) (1)

Revenue Growth Rate (Linear):-0.5%

Other Growth Rates (2)

Gross Profit Growth Rate (Linear):2.2%
Book Value Growth Rate (Linear):-50.0%
C. Company Profile & Context

Corporate Information (6)

Symbol:DYAI
Company Name:DYADIC INTERNATIONAL, INC.
Sector:Healthcare
Industry:Biological Products, (No Diagnostic Substances)
Exchange:NASDAQ
Country:United States

Market Classification (3)

Market Cap Category:N/A
Price Category:penny
Volume Category:N/A

Share Structure (3)

Shares Outstanding:36.44M
Shares Outstanding Basic:36.44M
Shares Outstanding Diluted:36.44M

Data Processing Info (3)

Processing Version:v3.0
Last Updated:2026-09-01 10:20:57 UTC
Data Timestamp:2026-08-21T01:19:24.734267
Scroll to Top